3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Leukemia, Myeloid, Chronic-Phase
6
Neoplasm Metastasis
4
Neoplasms
3
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia
2
Synovitis, Pigmented Villonodular
1
Sarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Giant Cell Tumor of Tendon Sheath
1
Genital Neoplasms, Female
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Chordoma
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Methotrexate
6
Cyclophosphamide
6
ponatinib
5
Cytarabine
5
merphos
4
Mycophenolic Acid
4
blinatumomab
3
Whole-Body Irradiation
3
Tacrolimus
3
Peripheral Blood Stem Cell Transplantation
3
Cyclosporine
3
venetoclax
2
fludarabine phosphate
2
bosutinib
2
Vincristine
2
Rituximab
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Idarubicin
2
Etoposide
2
Cladribine
2
CT-P10
2
Busulfan
2
prednylidene
1
pegfilgrastim
1
nilotinib
1
midostaurin
1
gilteritinib
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blast Crisis
×
nilotinib
×
1 year
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled